Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Pfizer Inc. (NYSE:PFE)

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 2.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,221,825 shares of the biopharmaceutical company's stock after acquiring an additional 81,899 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of Pfizer worth $106,981,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth $28,000. Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth $30,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE traded up $0.41 during midday trading on Tuesday, reaching $24.67. The company's stock had a trading volume of 7,783,887 shares, compared to its average volume of 41,800,464. The stock has a market cap of $140.23 billion, a P/E ratio of 17.89, a PEG ratio of 0.89 and a beta of 0.58. The company has a fifty day simple moving average of $24.07 and a 200 day simple moving average of $24.71. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.97%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Morgan Stanley boosted their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, Bank of America boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.